Better health experiences require empowered patients. Ada’s end-to-end Care Journey solution was built to connect patients to the right care, at the right time. Our world-class medical-AI symptom assessment and care navigation platform guides patients to appropriate treatment and care pathways. We help pharmaceutical organizations ease patient journeys through intelligent technology. 60m+ patients already have access to Ada, with partners trusting Ada for our medical accuracy, safety, and integrated user experience.
ZS is a management consulting and technology firm focused on transforming global healthcare and beyond. We leverage our leading-edge analytics, plus the power of data, science and products, to help our clients make more intelligent decisions, deliver innovative solutions and improve outcomes for all. Founded in 1983, ZS has more than 12,000 employees in 35 offices worldwide.
S3 Connected Health are the specialist digital health partner for life sciences companies.
We create regulated digital health solutions, from digital companions, chronic disease, and treatment management to digital therapeutics, that improve the lives of people with acute and chronic conditions.
We have delivered award-winning, regulatory-compliant solutions across 20 therapy areas and in more than 50 countries. Our scalable and secure solutions improve disease management, differentiate pharma products, and deliver new therapeutic interventions.
Affinial, our digital health platform offers our partners the opportunity to develop custom digital health solutions that address specific patient and disease challenges, while leveraging pre-built services that provide best practice implementation with a reduced cost and time to market.
S3 Connected Health supports our partners in pharma at all stages of their journey, from discovery through to solution creation and operation of regulated digital health solutions that fit corporate and brand commercial strategies.
Part Consulting. Part Technology. Fully Human.
Monstarlab accelerates growth for some of the world’s largest companies by keeping humans at the heart of digital transformations. We re-imagine business propositions through the alchemy of creative cross-discipline consulting, delivered through end-to-end transformation capabilities spanning strategy, service and experience design, systems integration, software development, data science and cloud services, all built on an agile culture of delivering change faster.
Empowering every collaborator in the healthcare value chain with innovative digital offerings such as customized application solutions, problem-solving engineering services, and technology expertise to conquer their most pressing business challenges. NewPage enables every stakeholder in the healthcare value chain to thrive at each stage of their digital transformation journey.
DiMe is the professional home for digital medicine. Together, we tackle the toughest digital medicine challenges, develop clinical-quality resources on a tech timeline, and deliver these actionable resources to the field via open-source channels and educational programs.
Created specifically for pharma, this Summit is designed to tackle key challenges around the integration of clinically-backed digital health solutions into the more traditional therapeutic engine of the pharmaceutical industry. With over 100 senior decision makers from every major pharma company, you can expect to walk away from the event with valuable industry connections and actionable takeaways.
From deep-dive presentations, multifaceted and interactive panel discussions and expertly-lead fireside chats, hear from the leaders of your field tackle key challenges, pick apart pain points and share areas of innovation set to break through the glass ceiling. Join the conversation and be a part of the digital health pioneers within the pharmaceutical industry.
Built by the industry, for the industry, this carefully crafted agenda is delivered by senior level decision makers across the pharmaceutical industry with an audience to match. You can expect to rub shoulders with the who’s who of the industry and network with those pioneering evidence-based digital health with pharma. You won’t want to sit this one out.
2023 Speaker Faculty
Meri Kay Scott is the Associate Vice President of Digital Health Research & Development at Eli Lilly. More than 20 years of global clinical development experience has provided Meri Kay with a breadth of work experiences in drug development, management, leadership, clinical trial development/execution, Clinical Project Management, Global Clinical Operations across therapeutic areas, and external partnerships (CRO, Alliances). Over this course of time, she has gained experience from early drug development to the market with a focus on Phase 2-4 programs in diabetes. She continually strives to have an impact, add value at all levels, and succeed in bringing new medicines to patients.
Shoibal Datta is Head, Digital Health Sciences within the Data Sciences Institute at Takeda. His team focuses on the incorporation of digital health technologies within clinical development specializing in decentralization of clinical trials, remote sensing and measurement and the development of digital health products for post-launch use.
Prior to Takeda he was Vice President of PPD Digital where he set the strategy of working with external platform partners and device manufacturers to create compliant, globally scalable approaches to conduct decentralized trials and their integration into conventional clinical research and data management processes. Prior to that, he spent 13 years at Biogen in roles within translational informatics, data sciences and as part of an innovation hub that launched MS PATHS, a learning healthcare system that utilizes technology to capture high quality data as standard of care for over 10,000 MS patients globally supporting RWE and value-based medicine initiatives.
Celine Marquez is the Global Medical Director of Digital Health at Genentech. She is physician trained in radiation oncology, and passionate about research, design thinking, innovation and the application of technology to improve patient outcomes and quality of life throughout lifespan.
Celine was awarded the UCSF Health Care Innovation Accelerator Award (which provides UCSF physicians with funding and startup experience for innovative ideas at the intersection of technology and medicine) and Isadora Rosenbaum Champion of Service Award in 2018.
Lauren Bataille is the Head of Digital Patient Health & Innovation, Cardiovascular, Renal & Metabolism (CVRM), at AstraZeneca. She is a clinical researcher with over a decade of experience working at the intersection of technology and healthcare. Lauren is currently leading digital transformation and trial innovations within pharma, serves as a board member of the Digital Medicine Society (DiMe) and as an advisor to MedTech startups.
Basker Gummadi, Head of Digital Health at Gilead Life Sciences, is responsible for leveraging Digital Health to provide the best possible patient experience. Prior to Gilead Mr Gummadi was a Senior Director, Digital Health responsible for R&D and Digital Health Commercialization across key Therapeutic Areas at BMS. He also led innovative initiatives that included building core capabilities for Digital Therapeutics.
Mr Gummadi spent several years at Bayer responsible for fostering a culture of Innovation, as well as laying the foundation for Digital Capabilities, by leading a team of Innovation Leaders to enable and exceed the Business Strategy. Mr Gummadi has great insights and experience in developing R&D Digital Vision, Business Architecture and Platforms to support Digital Medicines delivery.
Mr Gummadi is passionate about innovation and teaches Clinical Trial Innovation at UCSD extension. All throughout his career he has been a visionary in using technology to transform the business process and bring value to stakeholders and customers.
Mr Gummadi earned his Master’s degree in Computer Science from George Mason University, USA and his Bachelor’s degree in Electrical Engineering from Osmania University, India, and continues to learn through his teaching interactions at UCSD.
James Williams is the Head of External Innovation and Alliances within Biogen Digital Health, dedicated to pioneering personalized and digital medicine in neuroscience. Previous roles in Biogen include leading large scale digital health research programs such as MS PATHS (Multiple Sclerosis Partners Advancing Technology and Health Solutions). Earlier in his Biogen career, James was the lead epidemiologist for multiple drug development programs including Tecfidera® and Spinraza®.
Prior to joining Biogen, James worked within the Division of Epidemiology at the Food and Drug Administration focusing on pre- and post-market drug safety issues and real-world evidence across multiple indications.
James received his PhD in Psychiatric Epidemiology, his MHS in Mental Health, and his BA in Neuroscience from the John Hopkins University. He also was an Adjunct Assistant Professor of Psychiatry and Behavioral Sciences at the Johns Hopkins University School of Medicine.
Throughout the last ten years, Ainslie has been committed to the development of digital health solutions to address unmet medical needs. As Head of Digital Health R&D at Otsuka Pharmaceutical Development and Commercialization, Inc, Ainslie provides R&D leadership for the digital health portfolio and initiatives including digital therapeutic, digital medicine and digital biomarkers. She is a key contributor in defining Otsuka’s digital health strategy and leads efforts to create new digital health processes for evidence generation. Earlier in her career, Ainslie worked in various development and medical roles across various psychiatric disease states including major depressive disorder, schizophrenia, and bipolar disorder. Prior to this, she trained as a clinical psychologist and practiced cognitive-behavior therapy and other evidence-based psychotherapies in a variety of disease states. Ainslie earned her Bachelor’s Degree in psychology before completing her Doctorate of Clinical Psychology (D.Clin.Psych), followed by an additional graduate program to receive Doctor of Philosophy (Ph.D.) in cognitive neuroscience from the University of Sydney, Australia.
Andrew L’Huillier is an Associate Director of Global Regulatory Affairs in Precision Medicine and Digital Health at GSK. His interests lie in immunology, stem cell science, and the intersections of these two subjects in human biology and medicine. He is actively exploring ways to better diagnose and treat related diseases. Andrew gained his BS in Biology from Saint Joseph’s University, after which he gained his PhD in Immunology from Rutgers University.
Dr. Mar Santamaria is a psychiatrist working at the intersection between drug development, digital medicine, technology and clinical trials at Pfizer. She has two decades of clinical experience treating patients with severe and enduring neuropsychiatric conditions, with special clinical interest in schizophrenia. Following her passion for clinical research she joined a Clinical Translational fellowship at Pfizer/Harvard, which lead her to a full time career in drug development. She has dedicated the last 5 years at Pfizer to advance Digital Sciences, taking on roles such as Primary Investigator and Clinical Global Lead on several drug development programs, with emphasis on Digital Health Technologies. She works at the Pfizer Innovation Research Laboratory (PfIRe Lab) in Cambridge, MA as part of a multidisciplinary team often comprised of clinicians, research scientists, data scientists, and engineers to develop and validate precise and accurate digital endpoints for therapeutic clinical trials.
Adam is an Executive Investment Director and is based in Boston. He focuses on investments in the digital health space. He is a trained scientist with a PhD in neuroscience from University of Geneva, University of Lausanne and EPFL, Switzerland. He has published several articles in international peer reviewed journals and lectured at international conferences on developmental neuroscience and retinal degeneration.
Adam started his career with Boehringer Ingelheim Corporate Market Access Team in 2012 as a Senior Global Payer Strategy Manager in Ingelheim, Germany. He was managing global pricing and market access strategies for the HCV and oncology portfolio and driving the development of innovative market access approaches and payment schemes. He then moved to the UK and Ireland in 2015 to head the Pricing and Contracting Team, working across the whole Boehringer Ingelheim prescription medicines portfolio. Adam returned to Germany in 2018 to lead the Strategic Market Access Initiatives as well as Tech Partnerships within the Global Healthcare Affairs and Patient Engagement Team. Prior to joining Boehringer Ingelheim Adam worked as a life sciences strategy consultant for IQVIA, IBM Watson Health Consulting and Simon-Kucher & Partners in Belgium, France, Germany, Poland and The United States. He also worked as a research assistant at Jules Gonin Eye Hospital in Lausanne, Switzerland and as a Junior Project Leader at AnalyCen in Poland and Sweden.
Dr. Jin Lee is the former Director of Digital Health at Astellas Pharma Inc. She focuses on new product development and commercialization globally. Dr. Lee formerly worked at the innovation centers and venture arms of Humana and Providence St. Joseph Health. She also co-founded and worked in multiple startups in the maternal/ child, education, and restaurant space. Based in Silicon Valley, Dr. Lee advises and invests in multiple digital health startups and accelerator programs. She also serves on multiple nonprofit boards, including the American Heart Association and the Healthcare Businesswomen’s Association. Dr. Lee is a Presidential Leadership Scholar (selected by four American presidential centers) and has been a featured speaker at multiple events such as the TEDxPeacePlaza, Sirius XM radio, SXSW, American Academy of Pediatrics, and Aspen Institute Childrens Forum. She received her Ph.D in Neuropsychology from the University of Oxford and BA in Biology and Neuroscience from the University of Pennsylvania.
Jeff is head of Digital Opportunities for Otsuka America Pharmaceutical Inc. In that role, he chairs the Otsuka Digital Pioneer Initiative which actively invests in digital mental health therapies and supporting technology. Jeff has more than 15 years of healthcare leadership experience and previously held roles at UnitedHealth Group and Children’s of Minnesota. Prior to entering healthcare, he spent time in the retail and technology industries. He is an active angel investor and sits on several boards. He holds an MBA from the University of Minnesota Carlson School of Management and a BA from Concordia College.
Rose Purcell, JD, MA, is a director on the Global Regulatory Policy and Innovation team at Takeda Pharmaceuticals. Prior to joining Takeda, Ms. Purcell served as a Regulatory Counsel at FDA’s Center for Drug Evaluation and Research’s Office of Medical Policy, where her work focused on policies related to the use of innovative technologies in drug development.
Eran Desheh leads Corporate Development and Strategic Partnerships activities at Ada Health, including pharma-related business.With over a decade of experience in digital health and pharma corporate development roles, Eran is specialized in deploying disruptive and entrepreneurial projects within large corporates and growth start-ups.Before joining Ada Eran founded E.M.F. Investments and held positions at American Well and Teva. Eran earned his financial and legal experience at Goldman Sachs and Goldfarb, Seligman & Co. He holds an LLB, BA Finance, and an MBA, all with honors, from Reichman University
Dr. Isaac R. Rodriguez-Chavez is a scientific and regulatory leader with expertise in Infectious Diseases, Viral Immunology, Viral Oncology, and Vaccinology. His experience covers the entire life cycle of medical products from basic, preclinical, interventional clinical research (phase I – IV), non-interventional clinical research, and post- marketing studies. He also has expertise in digital health technologies (DHTs), modern clinical research strategy and operations, regulatory affairs, approval or licensure of medical products, and quality control and quality assurance. Currently, he is an independent consultant for clinical research (scientific-, clinical-, regulatory-affairs), and DHTs. Past positions over the last 25 years include: Senior Vice President for Scientific, Clinical Affairs, leading the Strategy of the Global Center of Excellence for decentralized clinical trials (DCTs) and Digital Medicine at PRA Health Sciences and ICON plc; FDA, CDER Senior Officer for Clinical Research Methodology, Regulatory Compliance and Policy Development modernizing clinical research through DCTs and Real World Evidence (RWE) enabled by DHTs and electronic Clinical Outcome Assessments (eCOAs); CEO and Founder, 4Biosolutions Consulting; Vice President, Research, Texas Biomedical Research Institute; Director of HIV Clinical Research Programs at National Institute of Allergy and Infectious Diseases (NIAID) and National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health (NIH); Senior Clinical Scientist, Schering Plough Corp. – Merck & Corp.; Scientist, Columbia University; Scientist, Polar Biotechnology Company and Venezuelan Institute for Scientific Research (IVIC). He has a PhD in Virology and Immunology; a MS in Microbiology; a MHS in Clinical Research and Health Sciences; and a B.S. in Biology. He also has 5 years of postdoctoral specialty experience in Clinical Research (phases 1 & 2 trials) linked to AIDS Malignancies, Immuno-Oncology and Viral Immunology (Infectious Diseases) done at the U.S. NIA and NCI, NIH. Dr. Rodriguez-Chavez is a Founding Board Member of the Digital Medical Society (DiME) and a former co-chair of the DiME’s Research Committee, driving digital medicine globally. He is an Advisory Board Member of BlueCloud by HealthCarePoint and Reveles Clinical Services; a co-Chair and regulatory Advisor of the Institute of Electrical and Electronics Engineers (IEEE) fostering industry standards on DCTs and DHTs. He is a Board Member of the Hypertrophic Cardiomyopathy Association (HCMA) and a Health Equity Council Member for equity, diversity and inclusion in rare diseases at the Global Genes. He is a global content editor for regulatory science and an Editorial Board Member of the DIA Global Forum Magazine. He is also an active member of sixteen professional associations, including the Infectious Disease Society of America, American Federation for Medical Research, American Association of Immunologists, American Society for Virology, American Society of Microbiology, Society of Quality Assurance, Association of Clinical Research Professionals, New York Academy of Sciences, International AIDS Society, International Association for Dental Research, American Association for Dental Research, and Regulatory Affairs Professional Society. He is a former Leadership Council Board Member of the Decentralized Trials & Research Alliance (DTRA).
Krista Russell is Takeda’s Head of Digital Health Solutions, having worked across the R&D portfolio of Takeda for 7 years. When Krista’s career in the US Navy ended abruptly due to injury, she chose to refocus her time and talents to clinical research.
Krista consistently works alongside business teams to create new and innovative solutions that directly impact people’s lives. She has a proven record of success helping teams design, implement and execute technology at all levels.
Kelly H. Zou, Ph.D., PStat® is Head of Global Medical Analytics and Real World Evidence, Viatris Inc. She is an elected Fellow of the American Statistical Association and an Accredited Professional Statistician. Previously at Pfizer Inc, she was Vice President and Head of Medical Analytics & Insights; Senior Director of Real World Evidence, Group Lead of Methods & Algorithms and Analytic Science Lead; Senior Director of Statistics. She was Associate Professor of Radiology at Harvard Medical School, as well as Director of Biostatistics at its affiliated teaching hospitals. She was Associate Director of Rates at Barclays Capital. She received both MA and PhD degrees in Statistics from the University of Rochester. She completed her Postdoctoral Fellowship at Harvard. Her research interests include health policy, real world evidence, signal detection, and artificial intelligence, with over 150 professional articles and 5 books. She was featured as an Outstanding Woman in Data Analytics by Forbes, an Inspirational Women in Statistics & Data Science by Wiley, and an Accomplished Woman in Statistics and Data Science by the American Statistical Association. She was the winner of the Chief Data and Analytics Officers’ Forum’s Future Thinking Award and Reuters Events Pharma USA’s Most Valuable Data & Insights Initiative Team Award.
Bhaskar Dutta is the Head of Digital Health Program Management at Alexion Pharmaceuticals. Bhaskar has over 14 years of experience in leading data science groups by defining the vision, executing strategic plans, and facilitating cross-functional alignments. He has delivered high-impact data science and AI solutions for the pharmaceutical industry, healthcare start-up, academia, and government.
Bhaskar received a Ph.D in Chemical and Biomolecular Engineering, Systems Biology, from the University of Maryland, and has published 24 peer-reviewed articles in high-impact journals, e.g., Nature Communications, Science Signaling, Cancer Cell, Oncogene, Nature Scientific Data, and Cell Systems.
Alisan is principal UX researcher & design thinking catalyst at Novo Nordisk A/S in Denmark. His work focuses on using design to improve the quality of care (QoC) for people living with chronic diseases. Since 2007, Alisan has partnered with Fortune 100 companies, universities, non-profits and start-ups where he led strategic innovation programs, service design initiatives, and NPD (new product development) projects.
For the past 20 years, Dr. Acacia Parks has made it her mission to bring evidence-based, destigmatized health care to the public. She is a digital health executive with deep knowledge of scientific, product, and regulatory strategy to support wellness, enforcement discretion, and 510k/DeNovo claims, and to meet expectations of enterprise, health care, pharma, and FDA audiences. Her consulting firm, Liquid Amber, supports digital health, DTx, and Pharma companies across a variety of therapeutic areas, including cancer, obesity, treatment-resistant depression, Alzheimer’s, social anxiety, ADHD, and chronic disease.
Geoff Eich is the CEO of Blue Note Therapeutics, a cancer supportive care company dedicated
to easing the burden of cancer and improving outcomes. Working closely with leading research
centers, community oncology, and patients, Blue Note develops clinically-validated digital
medical devices designed to improve outcomes, provide stigma-free access, and enable
efficient use of healthcare resources. Blue Note’s lead product attune™ is under review at FDA.
From 2007 to 2019 as an executive at Amgen, Inc, Geoff led teams across R&D, Regulatory,
Access, Commercial, Innovation and Digital Health. He also led the company’s Danish and
Icelandic affiliates while living with his family in København.
Geoff has deep experience in U.S. and EU healthcare, from establishment of legislative,
regulatory, and reimbursement pathways for low cost cancer and autoimmune therapeutics, to
development, approval, and commercialization of Amgen’s novel therapeutic medicines.
From 1995 to 2007, Geoff served as a U.S. Marine Corps pilot, including combat operations in
Iraq and Afghanistan. He holds a bachelor’s degree from the U.S. Naval Academy at Annapolis
and an MBA from the University of Maryland. Geoff is married with two teenage children and is
a Rotary Paul Harris Fellow. He enjoys travel, hiking, mountain biking and offroad motorcycles
with friends and family.
Bill Rush is a Senior Director, Value and Access, Digital Healthcare Solutions, at Sanofi, where he is responsible for developing and implementing launch strategy and execution plans to support the Digital Healthcare. Bill received a MBA in Finance from Loyola University Maryland, and has worked in the healthcare industry for over 12 years.
Joanna Kemp is a Senior Director and Digital Health Commercialization Lead, Hematology and Cell Therapy, at Bristol Myers Squibb. Joanna has spent most of her career in oncology in various roles at institutions including NYP Weill Cornell, Yale University, and Boston Medical Center. She also served as Nursing Director and Administrative Director of Cancer Clinical Trials at Beth Israel Deaconess Medical Center from 2016-2020, managing strategic direction and oversight of 70+ cross functional staff and a portfolio of 250+ clinical trials.
Ofer Waks is a Director of Digital Strategy and Innovation at Pfizer, where he leads cross-functional, scalable innovation programs, as well as digital product scoping, development, and management. He also leads external digital health company assessments, strategic partnership generation, and use case development from ideation and scoping to refinement and implementation. Ofer received a Bachelor of Pharmacy from Ben-Gurion University of the Negev, before going on to gain an MBA in Healthcare Management from The Wharton School.
Cris joined Sanofi Ventures as Partner in 2020 to lead venture capital investments and strategy in Digital Health & Data Science Innovation, globally. He holds a 20 year track record of building and launching emerging technologies, startups and innovation platforms with some of the largest organizations in the world.
Prior to Sanofi, Cris was a founding team member of Johnson & Johnson Innovation and Global Head of Digital Innovation since 2013. He held chief digital and data responsibilities, driving strategy and external tech collaborations throughout J&J’s Innovation Centers, JLABS incubators and JJDC corporate ventures across the Pharmaceutical, Consumer and Medical Device businesses. Previously, Cris led emerging technology programs within Research Informatics at Novartis for 6 years.
With entrepreneurial DNA, Cris is most notably known for his role in the innovation economy since Co-Founding Ultra Light Startups, the oldest and largest startup-investor pitch accelerator in Boston and New York City with additional chapters in Silicon Valley and London. ULS accelerated 700+ bootstrapping startups with 26% having gone on to raise angel/venture funding, leading to multiple acquisitions by companies such as Apple, Trip Advisor and Singapore Telecom.
Cris holds a Master of Science in Computer Information Systems from Boston University and a Bachelor of Science in Business Administration Ecommerce from Suffolk University. He is a recipient of multiple healthcare innovation awards, including 40 under 40 Innovator by the Boston Business Journal, and Top 40 Healthcare Transformer by MM&M Magazine. Cris currently serves on the boards of Empatica. Nucleai, Medisafe, Click Therapeutics, Omada Health, and Aetion. He is also on the advisory boards of the American Telemedicine Association, SXSW Health, Voice by Amazon Alexa and the Boston University School of Public Health Innovation Council.
Madalina Sucala, PhD, MBA is a behavioral scientist and digital health strategist with over 10 years of experience in digital health, merging scientific rigor with a keen focus on patient needs to improve health outcomes and overall treatment experience. She brings a combination of academic and industry-acquired expertise in developing, implementing, and evaluating digital health solutions for wider reach and impact. Dr. Sucala currently works as a Director of Digital Health Science, Oncology R&D, AstraZeneca, focusing on unmet evidence generation needs and leveraging technology solutions that enable patient-centric clinical trials.
Rakhshita Dhar is a Senior Director of Pharma Venture Investments at Leaps by Bayer. Rakhshita gained a Master of Science in Biochemistry and Molecular Biology from Georgetown University.
Kaitlyn O’Connor is a Partner at Nixon Gwilt Law. Kaitlyn combines her knowledge of business law and healthcare to provide real-world solutions for clients navigating this uniquely complex intersection.
Kaitlyn’s areas of practice include digital health, medical cannabis law and policy, telehealth, teledentistry, fraud and abuse, and HIPAA privacy/security. She provides legal, regulatory, and business guidance to healthcare providers across the spectrum of care, as well as early-stage companies and vendors serving the healthcare industry. Kaitlyn specializes in remote patient monitoring (RPM) and leads NGL’s RPM practice alongside Managing Partner Carrie Nixon. Kaitlyn particularly enjoys working with innovative RPM vendors to implement practical business solutions and accelerate growth in this rapidly expanding industry.
After graduating magna cum laude from Syracuse University, Kaitlyn attended William & Mary Law School, where she served as a member of the Business Law Review. She is a member of the Virginia Bar Association, the Connected Health Initiative (CHI), and the Virginia Cannabis Industry Association (VCIA) and serves as a Mentor for Jumpstart Foundry, an investment group focused on healthcare technology.
Amir is a Digital Health Freelance Advisor and a Global Thought Leader at the forefront of clinical research and data intelligence. Amir is inspired by the power of AI-driven technology to enable the detection and treatment of various diseases and improve patient care. Amir is the Head of Strategic R&D, Digital Health Innovation & Corporate Strategy at Mitsubishi Tanabe Pharma America, where he works closely with the company leadership to help drive a multi-year global enterprise strategy for incorporating tech innovation, digital biomarkers, AI-based analytics approaches, and digital health solutions across key therapeutic areas, including ALS, Spinal Cord Injury, Parkinson’s Disease, and Erythropoietic Protoporphyria (EPP).
Starting his career as a brain scientist at Harvard, Amir has over two decades of clinical experience in the biotech and healthcare industries. He currently sits on the Advisory Board of leading MedTech companies and holds several strategic consulting roles with both Pharma and HealthTech startups. Formerly, Amir was the Head of Digital Innovation at Pfizer, leading the development of digital solutions for neurodegenerative and rare diseases. Prior to pharma, Amir was a PI on numerous clinical trials as a Neurology Faculty and Professor of Pediatrics at Harvard Medical School. Amir has 300+ abstracts, manuscripts, peer-reviewed publications, and conference presentations worldwide.
Jordan Silberman, MD, PhD has a passion for evidence-based innovation in digital health. He serves as Director of Clinical Analytics and Research, Digital Care Solutions, Carelon Digital Platforms, Elevance Health (Formerly Anthem, Inc.). Jordan co-founded Anthem’s Digital Health Evidence Committee and leads a Digital Medicine Society workgroup on clinical evidence standards in digital health. At Anthem, Jordan leads scientific and statistical strategy for digital health initiatives including the Asthma Digital Study (tinyurl.com/5cfnkwxy), a randomized controlled trial. A behavioral scientist and experienced data analyst, Jordan has more than a decade of experience in digital health. He applies rigorous health economics and outcomes research (HEOR) and real-world evidence (RWE) approaches to evaluate digital health interventions. Jordan earned an MD (honors in research), a PhD (psychology), and a certificate in statistics from the University of Rochester, as well as a master’s degree in psychology from the University of Pennsylvania.
Zarina has over 17 years of experience in R&D Health Tech 0-1 product development. Her expertise has been utilized in a variety of digital health, digital therapeutics, genomics, virtual trials, and clinical trial initiatives at esteemed healthcare orgs such as Mayo Clinic, Mount Sinai, Memorial Sloan Kettering, AstraZeneca, and health-tech startups. Before this she worked as a multi-platform game engineer, releasing titles on hand-held devices and consoles in the global market.
The inaugural Evidence-Based Digital Health in Pharma Summit will be held at the Boston Park Plaza Hotel.
Located in Back Bay, this downtown hotel puts you within steps of Boston’s history, culture, shopping, dining, and entertainment.
We look forward to welcoming you to Boston this May.
Bringing together senior-level executives from across the industry, the Evidence-Based Digital Health in Pharma Summit promises an unrivalled networking and learning opportunity for everyone working in this space.
Our summit provides a rare opportunity to showcase your offering to a dedicated, world-class audience. Spaces are limited this year, please contact our commercial manager, Mariana (firstname.lastname@example.org) to discuss opportunities for involvement.
Register for the Event
For pricing and booking options please click the button to go to the registration page.